LS Mtron Participates in ‘Agritechnica 2019’ Accelerating Its Advance into Europe
28.11.2019 11:00:00 EET | Business Wire | Press release
LS Mtron (CEO Andy Kim) announced on November 28 that it had participated in ‘Agritechnica 2019’ held in Hanover, Germany from November 10 through the 16.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005173/en/
LS Mtron of Korea, specializing in industrial machines and state-of-the-art components, participated in ‘Agritechnica 2019’. The company has participated in the exhibition since 2015. This year, LS Mtron had a booth covering 205 square meters to showcase its products. Under banners reading “Change Your Standard,” LS Mtron exhibited products that stressed both ‘reliability’ and ‘rationality’. In particular, tractors featuring innovative futuristic design and technology were favorably received by visitors. (Photo: Business Wire)
Under banners reading “Change Your Standard,” LS Mtron exhibited products that stressed both ‘reliability’ and ‘rationality’. In particular, tractors featuring innovative futuristic design and technology were favorably received by visitors.
In 2003, LS Mtron was spun off from LG Group as an affiliate specializing in industrial machines and state-of-the-art components. Last year, sales amounted to KRW1.1 trillion. LS Mtron, with its annual production capacity of 50,000 units, has the largest share of the Korean tractor market. The company also exports to more than 40 countries, including the US, Brazil, China, etc., with its global production and sales bases playing key roles.
Significantly, last year, LS Mtron received the ‘Tractor of the Year’ award at the North American Equipment Dealers Association’s ‘Dealer’s Choice’ awards for the 5th consecutive years. In addition, LS Mtron is ‘Korea’s No.1 Tractor’ maker that is using ICT technology to lead the agricultural machinery industry in remote diagnostic services and cutting-edge autonomous tractor technologies.
This year, LS Mtron had a booth covering 205m2 to showcase its products in ‘Agritechnica 2019’. The slogan for the event ‘Change Your Standard’ was chosen to present maximum reliability and rationality to European customers and change the anchor purchases with excellent product fundamentals, innovative design, compelling performance, full support for dealers, and supplying parts at the right place at the right time.
LS Mtron introduced 7 models ranging from an 18ps Sub-compact model to the 150ps Row-crop model which can appeal to European customers. The futuristic ‘MTX (tentative)’ concept tractor is thought to have taken the streamlined design of existing products a step further. The company has applied a strong and sharp design language with headlamps resembling the fierce eyes of an angry bull that clearly say that LS Mtron products can provide ‘powerful and faithful work performance’. The Utility tractor, 100ps ‘XP’ model, scheduled to be launched in Europe in 2020 especially drew the attention of visitors. The XP tractor, based on its powerful engine and cutting-edge technology, makes it possible to move forward and backward easily without the manual operation of clutches when using the improved power shuttle. And as it comes standard with LED headlamps instead of halogen, its workability at night has also been improved.
In particular, during the exhibition, LS Mtron entered into an MOU for the development of e-Tractors with Austria’s AVL, the world’s best powertrain development and testing company. The two companies are planning to capitalize on this MOU to develop Sub-Compact e-Tractors and produce highly-efficient and eco-friendly tractors. LS Mtron will proactively present the direction of its eco-friendly models of the future to the European market and introduce a broader lineup of various models to make inroads into the lawn & garden and landscaping markets.
LS Mtron is planning to leverage its participation in the exhibition to develop new models and technologies customized for Europe. The company has established a roadmap for the launch of new models starting with the new premium MT2 and utility tractors in 2020 and plans to proactively respond to environmental protection and regulatory changes by successively launching new models based on the Stage V engine in 2021. In January 2020, LS Mtron will become the first Korean company in the industry to restrict the use of hazardous materials containing phthalates, thereby promoting the safety of customers and eco-friendliness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191128005173/en/
Contact information
LS Mtron
Jae Woo Lee
+82-31-8045-9667
unforgiven81@lsmtron.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
